People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Experts highlight interventions to support muscle and nutrient preservation during GLP-1 treatment and offer practical ...

The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.

The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But ...

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes ...

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.